Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 18.
doi: 10.1038/s41418-025-01534-3. Online ahead of print.

Endothelial cells-derived SEMA3G suppresses glioblastoma stem cells by inducing c-Myc degradation

Affiliations

Endothelial cells-derived SEMA3G suppresses glioblastoma stem cells by inducing c-Myc degradation

Peng-Xiang Min et al. Cell Death Differ. .

Abstract

The poor prognosis of glioblastoma (GBM) patients is attributed mainly to abundant neovascularization and presence of glioblastoma stem cells (GSCs). GSCs are preferentially localized to the perivascular niche to maintain stemness. However, the effect of abnormal communication between endothelial cells (ECs) and GSCs on GBM progression remains unknown. Here, we reveal that ECs-derived SEMA3G, which is aberrantly expressed in GBM patients, impairs GSCs by inducing c-Myc degradation. SEMA3G activates NRP2/PLXNA1 in a paracrine manner, subsequently inducing the inactivation of Cdc42 and dissociation of Cdc42 and WWP2 in GSCs. Once released, WWP2 interacts with c-Myc and mediates c-Myc degradation via ubiquitination. Genetic deletion of Sema3G in ECs accelerates GBM growth, whereas SEMA3G overexpression or recombinant SEMA3G protein prolongs the survival of GBM bearing mice. These findings illustrate that ECs play an intrinsic inhibitory role in GSCs stemness via the SMEA3G-c-Myc distal regulation paradigm. Targeting SEMA3G signaling may have promising therapeutic benefits for GBM patients.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: All animal experiments were performed in accordance with NIH and relevant guidelines for the care and use of laboratory animals of Nanjing Medical University in China, and approved by the Institutional Animal Care and Use Committee at Nanjing Medical University (IACUC-1912036). Human samples were obtained with informed consent of patients, and all experimental procedures were performed in accordance with the recognized ethical guidelines of the Declaration of Helsinki (2013), and approved by the Ethics Committee of the Third Affiliated Hospital of Nanjing Medical University ([2024]KY034-01).

Similar articles

References

    1. Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329:574–87. - PubMed - PMC - DOI
    1. Gilbertson RJ, Rich JN. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733–6. - PubMed - DOI
    1. Testa E, Palazzo C, Mastrantonio R, Viscomi MT. Dynamic interactions between tumor cells and brain microvascular endothelial cells in glioblastoma. Cancers. 2022;14:3128.
    1. Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y, et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther. 2024;9:149. - PubMed - PMC - DOI
    1. Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol. 2012;181:1126–41. - PubMed - PMC - DOI

LinkOut - more resources